BiotechTube
Home/Pipeline/Second-generation telomere targeting agents

Second-generation telomere targeting agents

Cancer

Pre-clinical/ResearchDiscovery and development

Key Facts

Indication
Cancer
Phase
Pre-clinical/Research
Status
Discovery and development
Company
MAIA Biotechnology

About MAIA Biotechnology

MAIA Biotechnology is focused on researching, developing, and delivering innovative medicines for cancer treatment, with a core platform centered on telomere targeting. The company's lead candidate, ateganosine (THIO), represents a novel approach that combines telomere disruption with immune system activation. MAIA is a publicly traded company (NYSE American: MAIA) advancing its pipeline of second-generation telomere-targeting agents.

View full company profile

Therapeutic Areas

Oncology

Other Cancer Drugs

DrugCompanyPhase
Shared Antigen mRNA Cancer VaccinesBioNTechPhase 2
Targeted Oncology TherapiesBioNTechPhase 1/2
ARGX-119ArgenxPhase 1
Oncology ProgramShionogiClinical
Bmab (Bevacizumab)BioconApproved
Ciforadenant (CPI-444)Corvus PharmaceuticalsPhase 1/2
Mupadolimab (CPI-006)Corvus PharmaceuticalsPhase 1
tovecimigCompass TherapeuticsClinical
CTX-8371Compass TherapeuticsClinical
XmAb 14045XencorClinical
XmAb 13676XencorClinical
VibostolimabXencorClinical